Huanggang Daily (reporter Lu Na's correspondent Shi Xiaohong) On May 13, good news came from Huanggang Luban Pharmaceutical Co., Ltd. The Hubei Province Cardiovascular and Cerebrovascular Drug Technology Enterprise School Joint Innovation Center jointly cooperated by the company and the Shanghai Institute of Pharmaceutical Industry successfully passed the evaluation of the Provincial Science and Technology Department in 2024. This is the fourth consecutive year that the innovation center has passed the evaluation.

Huanggang Luban Pharmaceutical Co., Ltd. is mainly engaged in the R&D, production and sales of characteristic pharmaceutical intermediates and APIs. In 2020, the company cooperated with Shanghai Pharmaceutical Industry Research Institute to establish the Hubei Province Cardiovascular and Cerebrovascular Drug Technology Enterprise School Joint Innovation Center to jointly carry out project research and development, improve the market competitiveness of enterprises and ensure sustainable development.

The innovation center has a high standard modern R&D laboratory and kilogram level laboratory, equipped with various R&D experimental equipment, which can accept the R&D and production of products with high synthesis difficulty, high separation difficulty, high added value and technical content. The product developed and industrialized by the Innovation Center, Omesartan Intermediates, has been recognized as the "single champion product of manufacturing industry in Hubei Province", and its market share is in the leading position at home and abroad, and is exported to India, Japan, South Korea, Britain and other countries; The other product, 1-ethyl - (3-dimethylaminopropyl) carbodiimide hydrochloride, was identified as "Hubei boutique".

The Innovation Center adheres to the development concept of "talents prosper enterprises, science and education prosper medicine", constantly develops new achievements, expands new fields, and has achieved a number of technological innovation achievements. It has obtained 14 authorized invention patents, 25 authorized utility model patents, 14 scientific and technological achievements, 1 provincial scientific and technological progress award, 1 leading group standard, and 1 participating in the formulation of national standards. It has been successively recognized as a provincial intellectual property demonstration construction unit and a national intellectual property advantage enterprise. In terms of research and development topics, the Innovation Center has undertaken the key special project of the Ministry of Science and Technology "Science and Technology Helps the Economy 2020", and the "Optics Valley Science and Technology Innovation Corridor Innovation Project", which will be guided by the central government in 2021 and 2023.

According to the relevant person in charge of Luban Pharmaceutical, it will continue to rely on the innovation center and extend to the downstream based on the pharmaceutical intermediates business to form an industrial chain based on the research and development of pharmaceutical intermediates and characteristic API products, so as to realize the steady, healthy and sustainable development of the company.